ClinicalTrials.gg
RecruitingNCT07573176Updated Nov 3, 2026

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

A Phase 3 interventional study of Seltorexant and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Recruiting at 53 sites in 7 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 3, 2026First sites in China and ArgentinaEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.

Planned enrollment
3rd of 12
600 · median 176
Started
2026
the only one that year
Phase 3
5 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
11 of 12
Janssen Research & Development, LLC

Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 3, and was the 12th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About seltorexant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing seltorexant in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder ([MDD], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet -5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features based upon clinical assessment and confirmed by the SCID-CT diagnosed with first depressive episode prior to age 55
  • Experienced at least one MDD episode prior to their current episode based on clinician-confirmed MDD diagnosis/MDE and documented in source records
  • Current episode of MDD must be a minimum of 8 weeks in duration and maximum of 24 months duration
  • Must meet one of the following criteria regarding current medication status.

    1. Can be presenting for a new episode of MDD with no adequate antidepressant treatment started in the current episode; however, must have been treated with an antidepressant medication in a prior episode for a minimum of 6 weeks at a stable dose at or above the minimum therapeutic level.

      OR

    2. Have taken up to two antidepressant treatments started in the current episode that were stopped (withdrawn), or will be withdrawn (washed out) due to inadequate response as defined by the Massachusetts general hospital antidepressant treatment response questionnaire (MGH-ATRQ)
  • (BMI) between 18 and 40 kilograms per square meter (kg/m\^2)
  • Must be medically stable on the basis of the following performed at screening and double-blind (DB) baseline: physical examination (including a brief neurological examination), vital signs (including blood pressure), and 12-lead (ECG)

Exclusion criteria

Exclusion criteria:

  • Use of ketamine/esketamine in the current depressive episode (up to 2 doses are allowed prior to screening)
  • Has treatment-resistant depression (TRD)
  • Has a primary diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia which has been the primary focus of psychiatric treatment within the past 2 years
  • Current active DSM-5 diagnosis of obsessive-compulsive disorder, posttraumatic stress disorder, anorexia nervosa, bulimia nervosa, or fibromyalgia
  • Has a history or current diagnosis of a psychotic disorder, bipolar disorder, autism spectrum disorder, borderline personality disorder, or somatoform disorders
  • Has dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • Has a current or recent history of homicidal ideation or serious suicidal ideation within the past 3 months or a history of suicidal behavior within the past 6 months
  • Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months
  • Has any significant sleep disorder, including but not limited to untreated/uncontrolled conditions
  • Has known allergies, , intolerance, or any to seltorexant or its
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Seltorexant

    Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (up to 6 months).

    Drug: Seltorexant

  • Placebo comparator
    Placebo

    Participants will receive matching placebo tablet orally once daily from Day 1 to Day 42 in double-blind treatment phase. Eligible participants who will enter the OL treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ EW visit (up to 6 months).

    Drug: Seltorexant · Drug: Placebo

Interventions

  • Seltorexant tablet will be administered orally.

    Also known as: JNJ-42847922

  • DrugPlacebo

    Placebo tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Double Blind (DB) Treatment Phase: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score in Participants with Major Depressive Disorder with Moderate-to-Severe Insomnia Symptoms (MDDIS)

    The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Time frame: Baseline up to Day 43

  2. Open-Label (OL) Treatment Phase: Number of Participants with Adverse Events Including Adverse Event of Special Interests (AESIs)

    An AE is any untoward medical occurrence in a clinical study participant administered with a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. The following AESIs are considered in this study: Suicidal thoughts, suicidal ideation, and suicidal behavior; Cataplexy; Sleep paralysis; Complex, sleep-related behaviors/parasomnias; Fall and Motor vehicle accident.

    Time frame: OL Baseline (Day 43) Up to 6 months

  3. OL Treatment Phase: Number of Participants with Vital Signs Abnormalities

    Number of participants with vital signs (blood pressure and pulse/heart rate measurements) abnormalities will be reported.

    Time frame: OL Baseline (Day 43) Up to 6 months

  4. OL Treatment Phase: Number of Participants with Suicidality Assessment using Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment. The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent.

    Time frame: OL Baseline (Day 43) Up to 6 months

  5. OL Treatment Phase: Number of Participants with Withdrawal Symptoms Assessment Using Physician Withdrawal Checklist (PWC-20)

    Potential withdrawal effects will be assessed by the PWC-20. The PWC-20 is a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 is a reliable and sensitive instrument for the assessment of discontinuation symptoms.

    Time frame: End of Treatment/Early withdrawal to end of the Follow-up visit (up to 14 days)

  6. OL Treatment Phase: Number of Participants with Abnormalities in Electrocardiogram (ECG)

    Number of participants with abnormalities in ECG will be reported.

    Time frame: OL Baseline (Day 43) up to 6 months

  7. OL Treatment Phase: Number of Participants Reporting Sexual Functioning using Arizona Sexual Experiences Scale (ASEX)

    The ASEX is a patient-reported 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. The scale has shown satisfactory reliability and validity.

    Time frame: Up to 6 months

  8. OL Treatment Phase: Change from Baseline in the Body Weight

    Change from baseline in body weight will be reported.

    Time frame: OL Baseline (Day 43) up to 6 months

  9. OL Treatment Phase: Change from Baseline in the Body Mass Index (BMI)

    Change from baseline in BMI will be reported.

    Time frame: OL Baseline (Day 43) up to 6 months

  10. OL Treatment Phase: Change from Baseline in the Waist Circumference

    Change from baseline in waist circumference will be reported.

    Time frame: OL Baseline (Day 43) up to 6 months

  11. OL Treatment Phase: Number of Participants with Abnormalities in Clinical Laboratory Parameters

    Number of participants with laboratory abnormalities related to hematology, serum chemistry will be reported.

    Time frame: OL Baseline (Day 43) up to 6 months

Secondary outcomes

  1. DB Treatment Phase: Change from Baseline in MADRS-Without Sleep Item (WOSI) Total Score

    MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity.

    Time frame: Baseline up to Day 43

  2. DB Treatment Phase: Change from Baseline in Sleep Disturbance using Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 10a(8a + 2a ) T-score

    The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance.

    Time frame: Baseline up to Day 43

  3. DB Treatment phase: Change from Baseline in MADRS-6 Total Score

    The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of major depressive disorder (MDD) symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms).

    Time frame: Baseline up to Day 43

  4. DB Treatment Phase: Proportion of Participants with Response on Depressive Symptoms Scale

    Responders are defined as proportion of participants with greater than or equal to (\>=) 50 percent (%) improvement in the MADRS total score from baseline to Day 43.

    Time frame: Baseline up to Day 43

  5. DB Treatment Phase: Change from Baseline in Sleep Disturbance using PROMIS-SD Short Form 8a T-Score

    The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance.

    Time frame: Baseline up to Day 43

  6. DB Treatment Phase: Change from Baseline in Patient Health Questionnaire 9-Item (PHQ-9) Total Score

    The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline up to Day 43

  7. DB Period: Change from Baseline in Work Productivity and Activity Impairment Questionnaire, Depression (WPAI-D) Scores

    The WPAI-D questionnaire is a patient-reported instrument to measure impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as the impairments in unpaid activity because of health problems during the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores are derived only for respondents who were working (should be missing for non-working), but the last score is applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. Negative changes in score indicates less impairment and greater productivity.

    Time frame: Baseline up to Day 43

  8. OL Treatment Phase: Change from Baseline Over Time in MADRS Total Score

    The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Time frame: OL Baseline (Day 43) up to 6 months

  9. OL Treatment Phase: Change from Baseline Over Time in Clinical Global Impression-Severity (CGI-S) Score

    The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience with the depression population, a participant is assessed on severity of illness at the time of rating according to the following criteria: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

    Time frame: OL Baseline (Day 43) up to 6 months

  10. OL Treatment Phase: Change from Baseline Over Time in MADRS-WOSI Total Score

    MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity.

    Time frame: OL Baseline (Day 43) up to 6 months

  11. OL Treatment Phase: Change from Baseline Over Time in Sleep Disturbance using PROMIS-SD Short Form 10a(8a+2a) T-score

    The PROMIS-SD 10a(8a+2a) is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD 10a(8a+2a) scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance.

    Time frame: OL Baseline (Day 43) up to 6 months

  12. OL Treatment Phase: Change from Baseline in Work Productivity and Activity Impairment-Questionnaire Depression (WPAI-D) Score

    The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores are derived only for respondents who were working (should be missing for non-working), but the last score is applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. Negative changes in score indicates less impairment and greater productivity.

    Time frame: OL Baseline (Day 43) up to 6 months

07

Study locations

53 of 53 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 27 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 27 months is close to that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
May 7, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Aug 24, 2028
CompletionEst.
May 3, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
17 sites added, 3 sites removed — first sites in China and Argentina
Show 17 added (11 United States, 2 China, 2 Argentina, 1 Brazil, 1 Canada)
  • Pharmax Research Clinic Inc · Miami, United States
  • Vector Clinical Trials · Las Vegas, United States
  • Future Search Trials of Dallas · Dallas, United States
  • Instituto Apice · Salvador, Brazil
  • Providence Care Hospital · Kingston, Canada
  • Beijing Huilongguan Hospital · Beijing, China
  • K2 Medical Research · Maitland, United States
  • Integrative Clinical Trials LLC · Brooklyn, United States
  • SPRI Clinical Trials, LLC · Brooklyn, United States
  • University of Pennsylvania · Philadelphia, United States
  • Baylor College of Medicine · Houston, United States
  • DM Clinical Research · Houston, United States
  • Sooner Clinical Research · Oklahoma, United States
  • R and H Clinical Research · Stafford, United States
  • Iternova Consultorios en Salud Mental · Córdoba, Argentina
  • Resolution · Mendoza, Argentina
  • Shanghai Mental Health Center · Shanghai, China
Show 3 removed
  • Integrative Clinical Trials LLC · Brooklyn, United States
  • SPRI Clinical Trials, LLC · Brooklyn, United States
  • Sooner Clinical Research · Oklahoma City, United States
across 2 updates, Oct 1, 2026 – Nov 3, 2026
Eligibility
5 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedMeet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features based upon clinical assessment and confirmed by the SCID-CT diagnosed with first depressive episode prior to age 55
  • EditedExperienced at least one MDD episode prior to their current episode based on clinician-confirmed MDD diagnosis/MDE and documented in source records
  • EditedCurrent episode of MDD must be a minimum of 28 weeks in duration and maximum of 24 months duration
  • EditedCan be presenting for a new episode of MDD onwith no adequate antidepressant treatment started in the current episode; however, must have been treated with an antidepressant medication in a prior episode for a minimum of 6 weeks at a stable dose at or above the minimum therapeutic level (medical record/source document).
  • EditedHave taken up to two antidepressant treatments started in the current episode that were stopped (withdrawn), or will be withdrawn (washed out) due to inadequate response or intolerance.as defined by the Massachusetts general hospital antidepressant treatment response questionnaire (MGH-ATRQ)
Oct 1, 2026
Show all 2 updates
  1. Nov 3, 2026
    11 sites added, 3 sites removed — first site in Argentina
    Show 11 added (8 United States, 2 Argentina, 1 China)
    • K2 Medical Research · Maitland, United States
    • Integrative Clinical Trials LLC · Brooklyn, United States
    • SPRI Clinical Trials, LLC · Brooklyn, United States
    • University of Pennsylvania · Philadelphia, United States
    • Baylor College of Medicine · Houston, United States
    • DM Clinical Research · Houston, United States
    • Sooner Clinical Research · Oklahoma, United States
    • R and H Clinical Research · Stafford, United States
    • Iternova Consultorios en Salud Mental · Córdoba, Argentina
    • Resolution · Mendoza, Argentina
    • Shanghai Mental Health Center · Shanghai, China
    Show 3 removed
    • Integrative Clinical Trials LLC · Brooklyn, United States
    • SPRI Clinical Trials, LLC · Brooklyn, United States
    • Sooner Clinical Research · Oklahoma City, United States
    + 1 other change: verification date
  2. Oct 1, 2026
    6 sites added — first site in China
    Show 6 added (3 United States, 1 Brazil, 1 Canada, 1 China)
    • Pharmax Research Clinic Inc · Miami, United States
    • Vector Clinical Trials · Las Vegas, United States
    • Future Search Trials of Dallas · Dallas, United States
    • Instituto Apice · Salvador, Brazil
    • Providence Care Hospital · Kingston, Canada
    • Beijing Huilongguan Hospital · Beijing, China
    Eligibility 5 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedMeet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features based upon clinical assessment and confirmed by the SCID-CT diagnosed with first depressive episode prior to age 55
    • EditedExperienced at least one MDD episode prior to their current episode based on clinician-confirmed MDD diagnosis/MDE and documented in source records
    • EditedCurrent episode of MDD must be a minimum of 28 weeks in duration and maximum of 24 months duration
    • EditedCan be presenting for a new episode of MDD onwith no adequate antidepressant treatment started in the current episode; however, must have been treated with an antidepressant medication in a prior episode for a minimum of 6 weeks at a stable dose at or above the minimum therapeutic level (medical record/source document).
    • EditedHave taken up to two antidepressant treatments started in the current episode that were stopped (withdrawn), or will be withdrawn (washed out) due to inadequate response or intolerance.as defined by the Massachusetts general hospital antidepressant treatment response questionnaire (MGH-ATRQ)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07573176
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Apr 30, 2026
Primary completion
Aug 24, 2028 (estimated)
Completion
May 3, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion